dopexamine hydrochloride

CLINICAL USE

Inotropic support in exacerbations of heart failure and heart failure associated with cardiac surgery

DOSE IN NORMAL RENAL FUNCTION

IV infusion

: 0.5 –1 mcg/kg/minute and then in increments (0.5–1 micrograms/kg/minute) up to 6 micrograms/kg/minute at not less than 15 minute intervals

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :429.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data

%Excreted unchanged in urine &nbsp &nbsp : 10

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.45

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :6–11 minutes/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function and adjust to response

10 to 20 &nbsp &nbsp : Dose as in normal renal function and adjust to response

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function and adjust to response

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide

Beta-blockers: risk of severe hypertension

Sympathomimetics: effects of adrenaline and noradrenaline possibly enhanced

ADMINISTRATION

Reconstition

–

Route

By intravenous infusion into a central or large peripheral vein

Rate of Administration

See dosage instructions

Comments

IV infusion

of 400 or 800 micrograms/mL in glucose 5% or sodium chloride 0.9%Peripheral administration: concentration of infusion solution must not exceed 1 mg/mL

Central administration: concentration not >4 mg/mLRate of administration and duration of therapy should be adjusted according to the patient’s response as determined by heart rate and rhythm, blood pressure, urine flow and measurement of cardiac output

OTHER INFORMATION

Avoid abrupt withdrawal

Tags: post-by-auto-php